Dr. Victoria McGuire of the Division of Cell Signalling and Immunology at CLS has been given a LEADERS Award by the Scottish Universities Life Sciences Alliance SULSA. These awards are given to early career researchers providing funding for training and personal development opportunities in parallel with their research careers. A major aim of the award scheme is to enable researchers work in a different lab to gain insight and new skills in a different research setting.
Vicky plans to use her award to undertake a three-month research placement in Oncology Bioscience with Dr. Darren Cross at Astra Zeneca this autumn.
Vicky who is a post-doctoral researcher with Dr. Simon Arthur at CSI, currently works on the signalling networks that control inflammation. She said, “I’m so gratified to have received this award and especially the opportunities it presents. I am excited at the prospect of taking time-out from academia and working in industry. With the growing importance of academic research for big pharma, the experience will be hugely significant in developing the translational aspect of my research work.”
Dr. Arthur said, “I am delighted that Vicky has received this award form SULSA to allow her to further develop her academic career. In addition to recognising her previous achievements it will provide her with the scope to develop her own ideas further. I'm sure that Vicky will make the most of the excellent opportunities that this award offers and I look forward to seeing how her career progresses.”
Colin Watts, Head of the CSI Division said: ‘I am delighted but not surprised that Vicky has received this award. It reflects not only her successful research record in diverse environments but also her demonstrable commitment to public engagement and outreach activities’
Darren Cross within Oncology Bioscience at AstraZeneca said: ‘We very much look forward to Vicky joining us on this placement, and pleased that Vicky has chosen AstraZeneca. I think this is a fantastic opportunity for both ourselves at AZ and Vicky, and will help further forge our links between pharma and academic research’